Nuclear Factor Kappa-B (NFKB1) Polymorphism and Organ Injury After Cardiac Surgery

Association of NFKB1 -94 Polymorphism With Lung and/or Kidney Injury After Cardiac Surgery With Cardiopulmonary Bypass

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00819871

Enrollment

105

Registered

2009-01-09

Start date

2008-05-31

Completion date

2008-12-31

Last updated

2013-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lung Injury, Kidney Injury, Single Nucleotide Polymorphism

Brief summary

NFKB1 -94ins/del polymorphism has been reported to be associated with reduced promoter activity of NFKB1 and several clinical diseases, but the clinical results cannot always be replicated. Besides, mutate allele is associated with alleviated inflammation in ulcerative colitis and some tumors, but aggravated inflammation in ARDS. The clinical value of this polymorphism remains controversial. This study was performed to investigate the association of NFKB1 -94ins/delATTG polymorphism with lung and/or kidney injury after cardiac surgery with CPB.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Chinese Han unrelated population * undergoing elective cardiac surgery with CPB

Exclusion criteria

* malignant tumor * autoimmune disease, immunodeficiency or immunosuppressive therapy * chronic renal disease (glomerular filtration rate \< 60ml/(min•1.73m2)) or liver dysfunction (Child Pugh classification\>A) * COPD, tuberculosis or other chronic pulmonary diseases * anemia with hemoglobin lower than 90mmHg * bleeding disorders * postoperative pericardial tamponade requiring re-operation * postoperative low cardiac output syndrome or acute pulmonary edema after left cardiac failure.

Design outcomes

Primary

Measure	Time frame
lung injury and/or kidney injury after cardiac surgery with cardiopulmonary bypass	24h after cardiac surgery

Secondary

Measure	Time frame
circulating level of CRP, TNF-alpha, IL-10; APACHE Ⅱ score; duration of ICU stay and hospitalization; death in 28 days	one month after cardiac surgery

Countries

China

Outcome results